Fig. 6: Impact of dose escalation on immunogenicity of VLP variants. | Nature Communications

Fig. 6: Impact of dose escalation on immunogenicity of VLP variants.

From: Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response

Fig. 6

A, B Immunogenicity of TLR agonist RNA40 encapsidated chimeric NDV VLP variants expressing the indicated HIV-1 envelope formulated with AS01 adjuvant given at an escalating dose of 500 μg. The immunogen was split into 7 IM immunizations in a dose-escalation manner. Four separate weeks of dose-escalation IM immunizations are indicated by the blue histogram. Serum neutralizing antibody titers of each rabbit are shown in dots, and the median value for each time point is connected with a solid line. C Heatmap of rabbit serum (Week 28) neutralization activity (ID50) against a panel of 10 HIV-1 Env pseudoviruses from clades (A–C) and SIVmac256.

Back to article page